Browsing Tag
Vera Therapeutics Inc.
1 post
Sefaxersen moves toward regulatory talks after Roche delivers positive Phase III IgAN result
Roche’s sefaxersen hits its Phase III IgAN endpoint as the company eyes regulatory talks in a fast-growing kidney disease market.